Abstract:
:Children with immune thrombocytopenia for ≥6 months completing a romiplostim study received weekly subcutaneous romiplostim (1-10 μg/kg targeting platelet counts of 50-200×109/L) in this extension to examine romiplostim's long-term safety and efficacy. Sixty-five children received romiplostim for a median of 2.6 years (range: 0.1-7.0 years). Median baseline age was 11 years (range: 3-18 years) and platelet count was 28×109/L (range: 2-458×109/L). No patient discontinued treatment for an adverse event. Median average weekly dose was 4.8 mg/kg (range: 0.1-10 mg/kg); median platelet counts remained >50×109/L, starting at week 2. Nearly all patients (94%) had ≥1 platelet response (≥50×109/L, no rescue medication in the previous 4 weeks), 72% had responded at ≥75% of visits, and 58% had responded at ≥90% of visits. Treatment-free response (platelets ≥50×109/L ≥24 weeks without immune thrombocytopenia treatment) was seen in 15 of 65 patients while withholding romiplostim doses. At onset of treatment-free response, the nine girls and six boys had a median immune thrombocytopenia duration of four years (range: 1-12 years) and had received romiplostim for two years (range: 1-6 years). At last observation, treatment-free responses lasted for a median of one year (range: 0.4-2.1 years), with 14 of 15 patients still in treatment-free response. Younger age at first dose and platelet count >200×109/L in the first four weeks were associated with treatment-free responses. In this 7-year open-label extension, three-quarters of the patients responded ≥75% of the time, and romiplostim was well tolerated, with no substantial treatment-related adverse events. Importantly, 23% of children maintained treatment-free platelet responses while withholding romiplostim and all other immune thrombocytopenia medications for ≥6 months. (Registered at clinicaltrials.gov identifier: 01071954).
journal_name
Haematologicajournal_title
Haematologicaauthors
Tarantino MD,Bussel JB,Blanchette VS,Beam D,Roy J,Despotovic J,Raj A,Carpenter N,Mehta B,Eisen Mdoi
10.3324/haematol.2018.202283subject
Has Abstractpub_date
2019-11-01 00:00:00pages
2283-2291issue
11eissn
0390-6078issn
1592-8721pii
haematol.2018.202283journal_volume
104pub_type
杂志文章相关文献
HAEMATOLOGICA文献大全abstract:BACKGROUND:Gastrointestinal bleeding is a frequent complication of liver cirrhosis (LC) and represents an important warning sign of imminent death. Platelet dysfunction is an abnormality occurring prevalently in severe liver failure, and could well predispose to bleeding. METHODS:One hundred and two patients with live...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1994-01-01 00:00:00
abstract::Advanced myelodysplastic syndrome harbors a high risk of progression to acute myeloid leukemia and poor prognosis. In children, there is no established treatment to prevent or delay progression to leukemia prior to hematopoietic stem cell transplantation. Azacitidine is a hypomethylating agent, which was shown to slow...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2016.145821
更新日期:2016-12-01 00:00:00
abstract::The stimulation of erythrocyte formation increases the demand for iron by the bone marrow and this in turn may affect the levels of circulating diferric transferrin. As this molecule influences the production of the iron regulatory hormone hepcidin, we hypothesized that erythropoiesis-driven changes in diferric transf...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2017.187245
更新日期:2018-10-01 00:00:00
abstract::The erythropoietin (Epo)-erythroferrone (ERFE)-hepcidin axis coordinates erythropoiesis and iron homeostasis. While mouse studies have established that Epo-induced ERFE production represses hepcidin synthesis by inhibiting hepatic BMP/SMAD signaling, evidence for the role of ERFE in humans is limited. To investigate t...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2019.233874
更新日期:2021-02-01 00:00:00
abstract:BACKGROUND:To date, multiple myeloma remains an incurable malignancy due to the persistence of minimal residual disease in the bone marrow. In this setting, monoclonal antibodies against myeloma-specific cell surface antigens represent a promising therapeutic approach, which is however hampered by a lack of appropriate...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2010.036814
更新日期:2011-10-01 00:00:00
abstract::We report the findings of the immunophenotypic profile of three cases of nasal T/NK cell lymphoma in leukemic phase. Flow cytometry analysis was carried out using cell suspensions of tumor nasal biopsies and peripheral blood. Tumor samples were composed by a mixture of a predominant subset of medium-size true NK cytCD...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.10654
更新日期:2007-02-01 00:00:00
abstract::Genetic events underlying pathogenesis of nodal and extranodal marginal zone lymphoma are not completely understood. We report here a novel t(X;14)(p11.4;q32.33) identified in 4 lymphoma cases: 2 with a mucosa-associated lymphoid tissue lymphoma, one with a nodal marginal zone lymphoma and one with gastric diffuse lar...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2011.052639
更新日期:2012-02-01 00:00:00
abstract::Distinct expression patterns of pro- and anti-apoptotic proteins may contribute to different prognoses and therapy outcomes in adult versus childhood acute myeloid leukemia (AML). Therefore, we investigated whether expression levels of apoptosis-related proteins CD95, Bcl-2, Bax, Bcl-xL, procaspase-3, XIAP, cIAP-1, an...
journal_title:Haematologica
pub_type: 信件
doi:
更新日期:2004-03-01 00:00:00
abstract::Elucidating the regulation mechanism of integrin αIIbβ3 is key to understand platelet biology and thrombotic diseases. Previous in vitro studies have implicated a role of migfilin in the support of platelet αIIbβ3 activation, however, contribution of migfilin to thrombosis and hemostasis in vivo and a detailed mechani...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2019.232488
更新日期:2020-11-01 00:00:00
abstract::Aplastic anemia is usually treated with immunosuppression or allogeneic transplant, depending on patient and disease characteristics. Syngeneic transplant offers a rare treatment opportunity with minimal transplant-related mortality, and offers an insight into disease mechanisms. We present here a retrospective analys...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2013.091074
更新日期:2013-11-01 00:00:00
abstract::e tested whether polymorphic variations in glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and interleukin-1 (IL-1beta and IL-1RN) genes confer susceptibility to mucosa-associated lymphoid tissue lymphomas (MALT) in a Chinese population. The rates of GSTM1, GSTP1, IL-1beta and IL-1RN genotypes did not differ bet...
journal_title:Haematologica
pub_type: 信件
doi:
更新日期:2004-08-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Treatment of acute myeloid leukemia (AML) in older patients remains unsatisfactory. The BGMT 95 trial for older patients set out to improve the outcome of these patients by adding a third drug (lomustine) to a 5+7 idarubicin and cytarabine schedule at induction and evaluating intermediate-dose...
journal_title:Haematologica
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.3324/haematol.11068
更新日期:2007-10-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:After allogeneic haematopoietic stem cell transplantation (SCT) the whole T-cell receptor (TCR) repertoire shows a markedly skewed pattern for 2-3 years. A small fraction of CD4+ T cells is represented by CD25+ regulatory lymphocytes (Treg), which play a crucial role in modulating peripheral t...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.10774
更新日期:2007-02-01 00:00:00
abstract::To investigate the role of oral contraceptives and their interaction with thrombophilia in ischemic stroke, a case-control study on women with a first ischemic stroke when younger than 45 years was carried out. Oral contraceptives doubled the risk of ischemic stroke in the first 6-18 months of use and hyperhomocystein...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2006-06-01 00:00:00
abstract:BACKGROUND AND OBJECTIVE:We analyzed the factors that affected the number and quality of peripheral blood stem cells (PBSC) collected for transplant in order to establish a minimum threshold for rapid hematopoietic recovery. DESIGN AND METHODS:From January 1995 to November 1996, a consecutive series of 67 patients, wi...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1998-06-01 00:00:00
abstract::Eleven patients with advanced APL were treated with ATO (0.15 mg/Kg daily). Eight (73%) achieved molecular CR, but 5 relapsed, 1 died in molecular CR, 1 was lost to follow-up and 1 is still alive in CR after allogeneic transplantation. We suggest that ATO may be effective also in advanced APL, but given the short CR, ...
journal_title:Haematologica
pub_type: 信件
doi:
更新日期:2004-05-01 00:00:00
abstract::Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation. Patients with neurofibromatosis type 1 harbor loss-of-function mutations in NF1 and have a 200- to 500-fold increased ri...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2015.136002
更新日期:2016-10-01 00:00:00
abstract:BACKGROUND AND OBJECTIVE:A magnetic resonance (MR) signal shows an inverse correlation with bone marrow cellularity. In this study, we investigated the possibility of estimating the degree of bone marrow cellularity by means of this non-invasive technique. METHODS:In 25 patients with different hematological disorders ...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1997-03-01 00:00:00
abstract::The introduction and the extended clinical use of nilotinib in the first-line treatment of chronic myeloid leukemia have been based on company-sponsored trials. Independent confirmations are extremely important. We report an investigator-sponsored study of nilotinib 300 mg twice daily in 130 chronic myeloid leukemia p...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2016.144949
更新日期:2016-10-01 00:00:00
abstract::Recently, the principles of density gradient cell separation have been transferred to the marrow fractionation, and the Ficoll technique by using a COBE 2991 blood cell processor has been developed and widely employed as well. This method is particularly useful in view of a chemical antineoplastic purging intended for...
journal_title:Haematologica
pub_type: 临床试验,杂志文章
doi:
更新日期:1991-03-01 00:00:00
abstract::Disease bulk is an important prognostic factor in early stage Hodgkin lymphoma, but its definition is unclear in the computed tomography era. This retrospective analysis investigated the prognostic significance of bulky disease measured in transverse and coronal planes on computed tomography imaging. Early stage Hodgk...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2016.141846
更新日期:2016-10-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) showed recurrent rearrangement of the BCL6 which is gene detected in 48% of cases analyzed by interphase-fluorescent in situ hybridization (FISH). These findings point to a critical role for BCL6 in the development of this distinct Hodg...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2004-08-01 00:00:00
abstract:UNLABELLED:Ruxolitinib, a JAK1/JAK2 inhibitor, is currently the only pharmacological agent approved for the treatment of myelofibrosis. Approval was based on findings from two phase 3 trials comparing ruxolitinib with placebo (COMFORT-I) and with best available therapy (COMFORT-II) for the treatment of primary or secon...
journal_title:Haematologica
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.3324/haematol.2013.095109
更新日期:2013-12-01 00:00:00
abstract::This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of 937 pati...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2017.186577
更新日期:2018-07-01 00:00:00
abstract:BACKGROUND:Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia and a poor tolerance of methotrexate. This latter problem is assumed to be caused by a higher cellular sensitivity of tissues in children with Down syndrome. However, whether differences in pharmacokinetics play a r...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2009.019778
更新日期:2010-07-01 00:00:00
abstract::Post-transfusion hepatitis (PTH) is a major problem in patients with acute leukemias requiring blood products during induction or consolidation therapy. In fact, PTH causes delays of chemotherapy with major violations in the timing of protocols. In order to assess the efficacy and safety of a short course of alpha-int...
journal_title:Haematologica
pub_type: 临床试验,杂志文章
doi:
更新日期:1991-09-01 00:00:00
abstract::We sought to confirm the prognostic importance of simple clinically available biomarkers of C-reactive protein, serum albumin, and ferritin prior to allogeneic hematopoietic cell transplantation. The study population consisted of 784 adults with acute myeloid leukemia in remission or myelodysplastic syndromes undergoi...
journal_title:Haematologica
pub_type: 杂志文章,多中心研究
doi:10.3324/haematol.2016.145847
更新日期:2016-11-01 00:00:00
abstract::We conducted a phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with relapsed, refractory myeloid leukemias. Twenty-eight patients received the construct intravenously at four dose levels (12, 18, 28 and 40 mg/m(2) per course) i...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2012.071092
更新日期:2013-02-01 00:00:00
abstract::BCL11A was the focus of recent studies on its inhibiting effect when bound onto the β-globin cluster in the mechanism of hemoglobin switching and HbF downregulation. We examined a cohort of 10 patients displaying different HbF levels and short deletions within the γβ-δ intergenic region to find a possible correlation ...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2012.061994
更新日期:2013-02-01 00:00:00
abstract:BACKGROUND:beta-thalassemia is one of the most common genetic diseases in the world and requires extensive therapy. Lentiviral-mediated gene therapy has been successfully exploited in the treatment of beta-thalassemia and showed promise in clinical application. Using a human beta-globin transgenic mouse line in a beta-...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.12010
更新日期:2008-03-01 00:00:00